The San Francisco company Nektar Therapeutics (NKTR) on Monday unveiled results from the first late-stage clinical trial showing its experimental, addiction-resistant opioid NKTR-181 reduces pain significantly more than a placebo in patients with chronic back problems.
The experimental opioid is designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids.
The drug, which by design reaches the brain slower than existing opioids to deter abuse, outperformed a placebo in over 600 patients with chronic lower back pain.
No comments:
Post a Comment